Takeshi Shimamura, PhD, MS

Takeshi Shimamura’s primary research interest is in the area of understanding the mechanisms that drive acquired targeted-drug resistance with a mesenchymal phenotype in non-small cell lung carcinoma (NSCLC) and small-cell lung cancer (SCLC). The goal of his research is to develop therapeutic strategies to overcome the acquired and de novo targeted-drug resistance using both in vitro and in vivo models.